The first FDA Fibromyalgia treatment drug is to be approved by 2008. The pharmaceutical industry is racing to try and gain approval since prescription drugs for Fibromyalgia is an untapped market.
The report appeared in Reuters News and it stated, “The contenders are looking to seize on a market now dominated by older anti-depressants as well as painkillers and other drugs. The competitors are big pharmaceutical giants like Pfizer, Eli Lilly and Forest Laboratories, Inc.
These competitors are anxiously racing to be the first to win the FDA clearance to market their Fibromyalgia treatment drugs. The research predicts that this market could reach $1 billion in less than 10 years.
There are FDA approved drugs that were created for other illnesses, but are used to treat Fibromyalgia. But the drug companies cannot market drugs specifically for Fibromyalgia until they receive clearance from the FDA.
Some of the drug contenders up for approval include:
Pfizers pregabalin (Lyrica)
This is a FDA approved drug that is used to treat nerve pain and seizures. You can read more about the clinical trial process of this drug by clicking here.
Eli Lillys duloxetine (Cymbalta)
Duloxetine is a drug approved as an anti-depressant that regulates two brain transmitters, serotonin and norepinephrine. You can read more about clinical trials on this drug by clicking here.
Forest Laboratories Milnacipran
Another serotonin/norepinephrine regulating drug that like duloxetine has been approved as an anti-depressant and is now completing Phase III FM pain trials is Forest Laboratories Milnacipran. You can read more information about this drug by clicking here.